Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
119 participants
INTERVENTIONAL
2011-06-30
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
NCT01030692
Medications for Stopping Cocaine Dependence and Preventing Relapse
NCT00218023
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
NCT00713583
Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
NCT00218075
Complementary Combination Therapy for Cocaine Dependence
NCT02538744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ldopa + ropinirole low dose
levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
levodopa/carbidopa
800/200 mg/d
Ropinirole 2 mg/d
2 mg/d
ldopa + ropinirole high dose
levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
levodopa/carbidopa
800/200 mg/d
Ropinirole 4 mg/d
4 mg/d
ldopa
levodopa/carbidopa 800/200 mg/d
levodopa/carbidopa
800/200 mg/d
placebo
Placebo
Placebo
sugar pill
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
levodopa/carbidopa
800/200 mg/d
Ropinirole 2 mg/d
2 mg/d
Placebo
sugar pill
Ropinirole 4 mg/d
4 mg/d
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* seeking treatment for cocaine dependence
* be in acceptable health based on medical history and physical exam
Exclusion Criteria
* have a medical condition contraindicating treatment with study medications
* having conditions of probation or parole requiring reports of drug use to officers of the court
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joy Schmitz
Professor - Psychiatry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Behavioral and Biomedical Sciences Building
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Suchting R, Green CE, de Dios C, Vincent J, Moeller FG, Lane SD, Schmitz JM. Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug Alcohol Depend. 2021 Nov 1;228:109054. doi: 10.1016/j.drugalcdep.2021.109054. Epub 2021 Sep 23.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA030787
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.